Actively Recruiting
Phase 12 Study of IDP-023 Alone and With Antibody Therapies for Advanced Blood Cancers Including Multiple Myeloma and Non-Hodgkins Lymphoma
Led by Indapta Therapeutics, INC. · Updated on 2025-06-03
128
Participants Needed
12
Research Sites
208 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating IDP-023, an off-the-shelf cell therapy made of natural killer NK cells, in patients with advanced blood cancers including relapsed or refractory multiple myeloma MM and non-Hodgkins lymphoma NHL. This open-label, first-in-human Phase 12 study aims to assess the safety, tolerability, and early anti-cancer effects of IDP-023 given alone or combined with immune therapies such as interleukin-2, isatuximab, daratumumab, or rituximab. The study is sponsored by Indapta Therapeutics, INC.
CONDITIONS
Brief Title
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Research Team
I
Indapta Therapeutics, Inc.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
